Dario's leading behavior change solutions continue to win
interest in the employer, payer and pharmaceutical markets
NEW
YORK, July 16, 2024 /PRNewswire/ -- DarioHealth
Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the
global digital health market, announced today a new contract with a
national employer to provide its cardiometabolic solution with
integrated support for GLP-1s to employees beginning in the third
quarter of 2024.
The employer, a leader in environmental services, selected
Dario's cardiometabolic suite to address multiple health
conditions, including diabetes, pre-diabetes, hypertension and
weight management needs, including integrated support for those
employees taking a GLP-1 medication. Dario's proven ability to
drive sustainable behavior change is key to helping employees
achieve successful outcomes while taking a GLP-1, as research shows
that 68% of people stop taking these medications within a year,
putting them at high-risk of regaining the weight
lost.1
Dario is proven to drive sustainable behavior change using
billions of data insights gathered from a decade of consumer
engagement to deliver highly personalized journeys that keep
members engaged over time. The enhanced engagement capabilities
inherited from the Company's acquisition of Twill bolster Dario's
ability to engage members for long-term success with enhanced
behavioral support.
"The challenges associated with GLP-1s make a behavior change
support program critical for any payer or employer in order to
deliver alongside access to the medications. Dario's expertise in
utilizing its platform to support behavior change and proven
outcomes gives employers confidence in our ability to drive lasting
results, especially now as we integrated Twill engagement
capabilities and behavioral support with access to providers and
peer-to-peer communities as integrated components in Dario's
intelligent platform," said Steven
Nelson, Chief Commercial Officer at Dario. "We believe that
employers, payers and pharmaceutical companies see tremendous value
in the combination of Dario and Twill as an integrated offering to
help solve the urgent challenges of GLP-1 management. In fact, we
expect at least ten of our employer clients to adopt our integrated
offering in the next quarter or so to leverage the power of our
enhanced multi-chronic condition platform."
1 Year-Two Real-World Analysis of Glucagon-Like Peptide-1
Agonist (GLP-1) Obesity Treatment Adherence and Persistency, Prime
Therapeutics/Magellan RX Management, 2024
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health
company revolutionizing how people with chronic conditions manage
their health through a user-centric, multi-chronic condition
digital therapeutics platform. Dario's platform and suite of
solutions deliver personalized and dynamic interventions driven by
data analytics and one-on-one coaching for diabetes, hypertension,
weight management, musculoskeletal pain and behavioral
health.
Dario's user-centric platform offers people continuous and
customized care for their health, disrupting the traditional
episodic approach to healthcare. This approach empowers people to
holistically adapt their lifestyles for sustainable behavior
change, driving exceptional user satisfaction, retention and
results and making the right thing to do the easy thing to do.
Dario provides its highly user-rated solutions globally to
health plans and other payers, self-insured employers, providers of
care and consumers. To learn more about Dario and its digital
health solutions, or for more information, visit
http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. related thereto contain or may
contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Statements that
are not statements of historical fact may be deemed to be
forward-looking statements. For example, the Company is using
forward-looking statements in this press release when it
discusses the expected timing of the launch of the solution,
the benefits that may be realized by members using Dario's
solutions, its belief that its expertise in utilizing its platform
to support behavior change and proven outcomes gives employers
confidence in its ability to drive lasting results, especially as
it now integrates Twill's engagement capabilities on its platform
and that it expects at least 10 of its employer clients will adopt
its integrated offering in the next quarter or so to leverage the
power of its enhanced multi-chronic platform. Without limiting
the generality of the foregoing, words such as "plan," "project,"
"potential," "seek," "may," "will," "expect," "believe,"
"anticipate," "intend," "could," "estimate" or "continue" are
intended to identify forward-looking statements. Readers are
cautioned that certain important factors may affect the Company's
actual results and could cause such results to differ materially
from any forward-looking statements that may be made in this news
release. Factors that may affect the Company's results include, but
are not limited to, regulatory approvals, product demand, market
acceptance, impact of competitive products and prices, product
development, commercialization or technological difficulties, the
success or failure of negotiations and trade, legal, social and
economic risks, and the risks associated with the adequacy of
existing cash resources. Additional factors that could cause or
contribute to differences between the Company's actual results and
forward-looking statements include, but are not limited to, those
risks discussed in the Company's filings with the U.S. Securities
and Exchange Commission. Readers are cautioned that actual results
(including, without limitation, the timing for and results of the
Company's commercial and regulatory plans for Dario™ as described
herein) may differ significantly from those set forth in the
forward-looking statements. The Company undertakes no obligation to
publicly update any forward-looking statements, whether as a result
of new information, future events or otherwise, except as required
by applicable law.
DarioHealth Corporate Contact
Mary Mooney
VP Marketing
mary@dariohealth.com
+1-312-593-4280
DarioHealth Investor Relations Contact
Kat
Parrella
Investor Relations Manager
kat@dariohealth.com
+315-378-6922
Media Contact
Scott
Stachowiak
Scott.Stachowiak@russopartnersllc.com
+1-646-942-5630
Logo: https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/dario-expands-glp-1-solution-client-base-with-new-employer-contract-302197846.html
SOURCE DarioHealth Corp.